Department of Ophthalmology. Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, 158 Shangtang Road, Hangzhou, 310014 Zhejiang, China.
Biomed Res Int. 2022 Aug 16;2022:5130416. doi: 10.1155/2022/5130416. eCollection 2022.
This study is aimed at investigating the efficacy of intraocular lens (IOL) implantation in patients suffering from glaucoma through meta-analysis of the previously published research. For this purpose, different literature databases were searched for identification of clinical studies published between January 2000 and January 2022 on evaluating IOL's efficacy in treating glaucoma. RevMan 5.3 was used to conduct a meta-analysis of the pertinent data. The central anterior chamber depth (ACD), corneal endothelial cell counts, best-corrected visual acuity (BCVA), intraocular pressure (IOP), anti-glaucoma medications (AGM), and axial length (AL) changes were compared, and the incidence of postoperative complications was thoroughly evaluated. The Cochran chi-square test was used to examine the heterogeneity of the evaluation results. According to the inclusion and exclusion criteria, 20 studies included 948 glaucomatous eyes. IOP was significantly lower than before treatment (MD = 8.64, 95 CI: 5.75-11.53; = 5.86, < 0.0001), while ACD increased significantly (MD = -1.38, 95 percent CI: -1.74-1.02; = 7.49, < 0.0001). The corneal endothelial cell counts were homogeneous (MD = 225.08, 95% CI: -64.17 to -514.33; = 1.53, = 0.20). AGM utilisation decreased (MD = 1.43, 95% CI: 0.752.12, = 4.09, < 0.0001). AL decreased significantly (MD = 0.31; 95% CI: 0.09-0.54; = 2.71; = 0.007). The incidence of complications remained insignificant after IOL treatment (OR = 1.05, 95% CI: 0.42 to 2.60; = 0.10, = 0.92; = 0.92). These findings indicate that IOL treatment can significantly reduce intraocular pressure, glaucoma drug use, and aqueous level (AL) in glaucoma patients while increasing the depth of the central anterior chamber. This study offers a theoretical foundation for selecting glaucoma treatment methods.
本研究旨在通过对以往发表的研究进行荟萃分析,探讨眼内晶状体(IOL)植入治疗青光眼的疗效。为此,检索了 2000 年 1 月至 2022 年 1 月期间评估 IOL 治疗青光眼疗效的临床研究文献,使用 RevMan 5.3 对相关数据进行荟萃分析。比较中央前房深度(ACD)、角膜内皮细胞计数、最佳矫正视力(BCVA)、眼内压(IOP)、抗青光眼药物(AGM)和眼轴(AL)的变化,并全面评估术后并发症的发生率。采用 Cochran chi-square 检验评估评价结果的异质性。根据纳入和排除标准,20 项研究纳入了 948 只青光眼眼。IOP 明显低于治疗前(MD = 8.64,95%CI:5.75-11.53; = 5.86,< 0.0001),而 ACD 明显增加(MD = -1.38,95%CI:-1.74-1.02; = 7.49,< 0.0001)。角膜内皮细胞计数具有同质性(MD = 225.08,95%CI:-64.17 至-514.33; = 1.53, = 0.20)。AGM 的使用率降低(MD = 1.43,95%CI:0.752.12, = 4.09,< 0.0001)。AL 明显降低(MD = 0.31;95%CI:0.09-0.54; = 2.71; = 0.007)。IOL 治疗后,并发症发生率仍无显著差异(OR = 1.05,95%CI:0.42-2.60; = 0.10, = 0.92; = 0.92)。这些发现表明,IOL 治疗可显著降低青光眼患者的眼内压、青光眼药物使用量和房水水平(AL),同时增加中央前房深度。本研究为选择青光眼治疗方法提供了理论依据。